XML 169 R39.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY AND MEZZANINE EQUITY (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Equity [Abstract]

SCHEDULE OF SERIES B PREFERRED STOCK

The following table illustrates the activity of the Series B Preferred Stock during the nine months ended September 30, 2024:

SCHEDULE OF SERIES B PREFERRED STOCK


Balance as of December 31, 2023		$	-

Issuance of 422,200 Series B Preferred Stock due to Offering			-
Accretion of Series B issuances			-
Balance of March 31, 2024			-

Issuance of 422,200 Series B Preferred Stock due to Offering			1,568,895
Accretion of Series B issuances			3,955,916

Issuance of 100,592 Series B Preferred Stock			1,307,696
Accretion of Series B issuances			1,378

Issuance of 5,000 Series B Preferred Stock			15,000
Series B Preferred Stock conversion of liability			50,000
Accretion of Series B issuances			1,082

Balance as of June 30, 2024		$	6,899,967
Balance			6,899,967

Issuance of 50,453 Series B Preferred Stock			655,889
Accretion of Series B issuances			12,440

Accretion of 422,200 Series B Preferred Stock due to Offering			106,418

Accretion of 5,000 Series B issuances			1,260

Accretion of 100,592 Series B issuances			25,355

Balance as of September 30, 2024		$	7,701,329
Balance			7,701,329

SCHEDULE OF CHANGES IN COMMON STOCK WARRANTS

										Weighted								Weighted
		Warrants Outstanding								Average								Average
		Number				Exercise				Remaining				Aggregate				Exercise
		Of				Price				Contractual				Intrinsic				Price
		Shares				Per Share				Life				Value				Per Share

Balance at December 31, 2023			2,608,734			$	0.008 – 16.00				4.81			$	1,624,905			$	0.44

Warrants granted			63,460,454			$	0.06				4.68			$	13,851,695			$	0.06
Warrants exercised			-			$	-				-			$	-			$	-
Warrants expired/cancelled			(98,803	)		$	0.008 – 16.00				-			$	-			$	-

Balance at September 30, 2024			65,970,385			$	0.06 – 16.00				4.66			$	13,851,695			$	0.06

Exercisable at September 30, 2024			65,970,385			$	0.06 – 16.00				4.66			$	13,851,695			$	0.06

Balance at December 31, 2022			-			$	-				-			$	-			$	-
Warrants acquired concurrent with the Titan Merger			108,734			$	0.008 – 16.00				0.62			$	35,702			$	9.29
Warrants granted			-			$	-				-			$	-			$	-
Warrants exercised/ exchanged			-			$	-				-			$	-			$	-
Warrants expired/cancelled			-			$	-				-			$	-			$	-

Balance at September 30, 2023			108,734			$	0.008 – 16.00				0.62			$	35,702			$	9.29

Exercisable at September 30, 2023			106,907			$	0.008 – 16.00				0.63			$	33,891			$	9.45

										Weighted								Weighted
		Warrants Outstanding								Average								Average
		Number				Exercise				Remaining				Aggregate				Exercise
		Of				Price				Contractual				Intrinsic				Price
		Shares				Per Share				Life				Value				Per Share

Balance at December 31, 2022			-			$	-				-			$	-			$	-

Warrants acquired concurrent with the Titan Merger			108,734			$	0.008 – 16.00				0.37			$	24,905			$	9.29
Warrants granted			2,500,000			$	0.06				5.00			$	1,600,000			$	0.06
Warrants exercised			-			$	-				-			$	-			$	-
Warrants expired/cancelled			-			$	-				-			$	-			$	-

Balance at December 31, 2023			2,608,734			$	0.008 – 16.00				4.81			$	1,624,905			$	0.44

Exercisable at December 31, 2023			2,606,907			$	0.008 – 16.00				4.81			$	1,623,641			$	0.45

Balance at December 31, 2021			-			$	-				-			$	-			$	-
Warrants granted			-			$	-				-			$	-			$	-
Warrants exercised/exchanged			-			$	-				-			$	-			$	-
Warrants expired/cancelled			-			$	-				-			$	-			$	-

Balance at December 31, 2022			-			$	-				-			$	-			$	-

Exercisable at December 31, 2022			-			$	-				-			$	-			$	-

Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, "the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit).

+ References + Details